Condition: Soft Tissue Sarcoma · Sponsor: QBiotics Group Limited
A Phase IIa open label study evaluating the preliminary efficacy of intratumoural tigilanol tiglate in advanced and/or metastatic soft tissue sarcoma of the extremities and body wall.
This description comes directly from the study's public registry record.
Head of Human Clinical Operations · +61 (0) 738 708 933 · enquiries@qbiotics.com
Always discuss trial participation with your own doctor first.
| Memorial Sloan Kettering Cancer Centre | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05755113